Skip to main content
. 2018 Jun 25;131(12):jcs213314. doi: 10.1242/jcs.213314

Fig. 8.

Fig. 8.

ARF6 inhibition enhances the anti-neoplastic effects of synthetic sphingolipids. (A) Viability of SupB15 cells treated with FTY720 (5 µM), SecinH3 (30 µM) or both. (B-E) Viability of different cell lines treated with 893 (4 µM), SecinH3 (30 µM) or a combination. (B) SW620 cells at 120 h. (C) PC3 cells at 144 h. (D) MCF7 cells at 120 h. (E) MDA-MB-231 cells at 96 h. (F) MDA-MB-231 cells at 96 h treated with 893 (4 µM) and NAV2729 (6.25 µM). (G) Peripheral blood mononuclear cell (PBMC) colony formation assay at the indicated doses of 893 and SecinH3. Means±s.e.m. shown for n≥3 in all panels. Using two-tailed t-test (A) or ordinary one-way ANOVA (B-G) to compare with controls: n.s., not significant; *P≤0.05; **P≤0.01; ***P≤0.001. Tukey's test was used to correct for multiple comparisons in B-G; statistics are relative to the respective control.